Skip to main content
. Author manuscript; available in PMC: 2021 Jul 18.
Published in final edited form as: Nat Metab. 2021 Jan 18;3(1):33–42. doi: 10.1038/s42255-020-00334-y

Extended Data Fig. 3. Doxycycline does not promote cell survival in MELAS or ND1 cybrid cells through the integrated protein response (ATF4) or reported protein targets.

Extended Data Fig. 3

a. Western blot of integrated response proteins in MELAS cybrid cells treated with doxycycline for 24 hours (n=2 experiments). b. Western blot of ATF4 in siATF4 MELAS cybrid cells (n=2 experiments). c. 48 hour low-glucose survival of siATF4 MELAS cybrid cells treated with doxycycline (n=3 biologically independent samples). d. 48 hour low-glucose survival of MELAS cybrid cells treated with doxycycline with or without ISRIB (Integrated Stress Response Inhibitor) (n=3 biologically independent samples over n=2 independent experiments) e. 48 hour low-glucose survival of MELAS cybrid cells treated with pan matrix-metalloprotease (MMP) inhibitor BB-94 (n=2 biologically independent samples). f. 4 day galactose survival assay of ND1 cybrid cells treated with BB-94 (n=2 biologically independent samples). g. 48 hour low-glucose survival of MELAS cybrid cells treated with the PARP inhibitor Olaparib (n=2 biologically independent samples). h. 4 day galactose survival of ND1 cybrid cells treated with Olaparib (n=2 biologically independent samples). i. 48 hour low-glucose survival of MELAS cybrid cells treated with the PAR1 inhibitor Vorapaxar (n=2 biologically independent samples). j. 8 day galactose survival of ND1 cybrid cells treated with Vorapaxar (n=2 biologically independent samples). k. Western blot of PAR1 in siF2R MELAS cybrid cells (n=2 experiments). l. 48 hour low-glucose survival of MELAS cybrid cells depleted of PAR1 (siF2R) (n=3 biologically independent samples). Data are presented as mean values +/− s.e.m. error bars, Student’s t-test with a two-stage linear step-up procedure of Benjamini, Krieger and Yekutieli, with Q = 5%, * q<0.05.